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The five subtypes (M 1 -M 5 ) of muscarinic acetylcholine (ACh) receptors (mAChRs) are prototypical members of Family A G protein-coupled receptors (GPCRs) (Caulfield, 1993) .
The M 1 , M 4 and M 5 mAChRs are predominantly expressed in the CNS, whilst M 2 and M 3 mAChRs are expressed widely in the CNS and periphery (Wess et al., 2007) . Of these receptors, the M 3 mAChR currently represents the predominant subtype with respect to established clinical therapies, having proven a tractable drug target for conditions such as chronic obstructive pulmonary disease and overactive bladder disorder (Wess et al., 2007) .
Nonetheless, subtype-selective targeting of mAChRs remains difficult due to the high degree of sequence conservation in the orthosteric binding site (Caulfield, 1993; Gregory et al., 2007) . One approach to circumvent this issue is to target alternative, allosteric, sites on these receptors (Birdsall and Lazareno, 2005) .
Although it is known that mAChRs possess more than one allosteric site Gregory et al., 2007) , most studies to date have focused on the so-called 'prototypical' allosteric site, which binds neuromuscular-blocking agents, such as gallamine and alcuronium, alkane-bis-ammonium compounds, including heptane-1,7-bis-dimethly-3'-pthalimidopropyl ammonium bromide, and alkaloid derivatives, such as brucine. This prototypical mAChR allosteric site is thought to encompass regions of the receptor's 2 nd and 3 rd extracellular loops, and the top of transmembrane (TM) domain VII (Avlani et al., 2007 ;
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using this system to study mammalian GPCR/G protein interactions was first demonstrated in studies of β 2 -adrenergic receptor coupling to mammalian Gα s proteins (King et al., 1990) .
Since then, further modifications to the yeast system have been made to accommodate mammalian GPCR signaling. One pivotal modification is the expression of a chimera consisting Gpa1 (yeast Gα protein) with a five C-terminal amino acid substitution from the mammalian Gα protein of choice (Brown et al., 2000; Dowell and Brown, 2002) . Using this approach, we uncovered novel G protein-biased signaling of M 3 mAChR ligands previously classed as traditional orthosteric 'antagonists', such as atropine, that was subsequently validated in mammalian cells (Stewart et al., 2010) . This exciting finding prompted the current study, where we investigated whether the S. cerevisiae platform could also be used to identify allosteric ligand-mediated functional selectivity, at the level of the G protein.
As proof-of-concept, we focused on the brucine-CCh interaction at the K 
Methods

Materials
The Surefire™ ERK1/2 phosphorylation kit was kindly donated by Dr Michael Crouch (TGR Biosciences, SA, Aust.). The p416GPD rM 3 Δ i3 mAChR was a generous gift from Dr Jürgen
Wess (NIH, Bethesda, MD) . The yeast strains were a kind gift from Dr Simon Dowell (GSK, purchased from GIBCO (Gaithersburg, MD) and JRH Biosciences (Lenexa, KS), respectively. Gα q or Gα 12 siRNAs were acquired from Applied Biosciences/Ambion (Austin, TX). All other reagents were purchased from Sigma Aldrich (St Louis, MO).
Yeast transformations and signaling assay
Saccharomyces cerevisiae strains expressing chimeras of five C-terminal amino acids of human Gα protein with Gpa1 (1-467) have been previously described in Brown et al. (2000) .
The yeast strains were further transformed with a p416GPD vector containing the gene encoding the rat M 3 muscarinic acetylcholine receptor (rM 3 Δ i3 mAChR) with an intracellular GACAGCTGCATAC-CCGAAACCTATTGGAATC 3' and 5' GATTCCAATAG-GTTTCGGGTATGCAGCTGTC 3', the vector containing the mutated gene was then transformed in the same manner as described above.
The conditions for the signaling component of the assay have also been previously described (Olesnicky et al., 1999) . Briefly, single colonies were cultured overnight at 30°C in synthetic complete (SC) medium, lacking amino acids required for plasmid maintenance. Cells were pelleted and diluted to 0.02 OD 600 mL -1 in SC medium, lacking amino acids, but supplemented with 0-10mM 3-aminotriazole, 1μM fluorescein di(β-D-galactopyranoside) and 0.1M sodium phosphate, pH 7.3. Cell suspensions were diluted into 96-well plates with various ligands and incubated for 18-24 h at 30°C. Fluorescence was measured in a Flexstation™ (Molecular Devices) using 485nm excitation and 520nm emission wavelengths.
Transfections and cell culture
The cDNA sequence of the human M 3 mAChR was amplified by PCR and cloned, using classical cloning methods, into the Gateway entry vector, pDONR201, using the BP clonase kit according to manufacturer's instructions. The M 3 mAChR construct was subsequently transferred into the Gateway destination vector, pEF5/FRT/V5-dest, using the LR clonase kit in accordance with manufacturer's instructions. The construct was then transfected into Flp-
In CHO cells using methods described previously (Nawaratne et al., 2008) . The same processes were applied to generate a vector containing the gene encoding the human This article has not been copyedited and formatted. The final version may differ from this version. harvested and centrifuged at 300 × g for 3 min. The intact cell pellet was suspended in homogenization buffer (20mM HEPES; 10mM EDTA; 0.1mg mL -1 saponin, pH 7.7) and further centrifuged (300 × g, 3 min). Cells were then resuspended in homogenization buffer and homogenized using a Polytron PT1200 homogenizer for two 10 s intervals at maximum setting (6), with 30 s cooling periods on ice between each burst. The homogenate was then centrifuged (40,000 × g, 1 h, 4°C). The resulting pellet was resuspended in 5 ml of HEPES buffer (100mM NaCl; 20mM HEPES; 10mM MgCl 2 , pH 7.4), and the protein content determined using a BCA assay kit (Pierce Biotechnology) according to the manufacturer's instructions, using bovine serum albumin as a standard. The homogenate was then divided into 1 ml aliquots and either used immediately or stored frozen at −80°C until required. 
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Radioligand binding assays
Data analysis
All data were analyzed using Prism 5.02 (GraphPad Software, San Diego, CA). For radioligand saturation binding data, nonspecific and total binding data were fitted to the following equation.
where Y is radioligand binding, B max is the total receptor density, [A] is the radioligand concentration, K A is the equilibrium dissociation constant of the radioligand, and NS is the This article has not been copyedited and formatted. The final version may differ from this version. presence of brucine were fitted to the following allosteric binding model (Christopoulos, 2000) :
where
and [ 
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where E is effect, E max and basal are the top and bottom asymptotes of the curve, respectively, Log[A] is the logarithm of the agonist concentration, pEC 50 is the negative logarithm of the agonist concentration that gives a response halfway between E max and basal (i.e,, -ve log. 
where E denotes the effect, A denotes the agonist, B denotes the allosteric modulator, α β denotes a composite cooperativity factor that quantifies the change in affinity ( that it cannot derive parameters that describe the molecular properties underlying agonism and allosteric modulation of signaling efficacy; the resulting parameters are composite values that also reflect the influence of receptor density and stimulus-response coupling on the observed responses.
All parametric measures of potency, affinity, operational efficacy, and cooperativity were estimated as logarithms (Christopoulos, 1998 E mAChR was coupled to Gpa1/Gα i1/2 , brucine had no effect on carbachol responsiveness. Additionally, from the data in yeast expressing the rM 3 Δ i3K 7.32 E mAChR and Gpa/Gα q or Gpa/Gα 12 , we derived brucine affinity (Log K B ), efficacy (Log τ B ) and cooperativity (Log α β ) estimates using equation 5 (Table 1) .
This article has not been copyedited and formatted. The final version may differ from this version. H]-NMS, CCh and brucine to determine the effect of brucine on the affinity of the radioligand and the non-radiolabeled orthosteric competitor ( Figure 2 ). From these data, brucine affinity and cooperativity values were derived using equation 2 (Table 3) . (Figures 4 and 5) . The results were consistent with those found in the yeast signaling assay for Gpa1/Gα 12 coupling, whereby brucine had no effect on the CCh concentration-response curves at the rM 3 Δ i3 mAChR, but was able to robustly potentiate CCh -induced signaling at the rM 3 Δ i3K
7.32 E mAChR, without displaying any allosteric agonism. In conjunction with generating a G protein profile for receptor-ligand interaction, we reasoned that another possible utility of pairing the yeast signaling assay with a functionally selective modulator could be to aid in the dissection of intracellular G protein mediators of a convergent signaling pathway. For the purposes of the current study, we chose the phosphorylation of ERK1/2 as one such pathway (Werry et al., 2006) . Specifically, the profile of the effect of brucine at different G protein subtypes may be used to predict which G protein (if any) underlies the predominant mode of coupling that leads to M 3 K 7.32 E mAChRmediated phosphorylation of ERK1/2. Therefore, the effect of brucine on ERK1/2 phosphorylation was investigated. Time-course studies were performed in CHO M 3 and 
of PTX pretreatment ( Figure 6 ). The lack of effect of PTX on M 3 K 7.32 E mAChR-mediated ERK1/2 phosphorylation suggested that G i/o proteins had no contribution to this pathway, as predicted. (Figure 7 ). Although the degree of direct allosteric agonism mediated by brucine itself in Ca 2+ mobilization assays was reduced by the presence of transfection lipid, robust potentiation of CCh-mediated signaling was still evident in the absence of siRNA ( Figure 7A ) as well as in the presence of Gα 12 siRNA ( Figure 7C ), but was significantly attenuated in upon transfection of Gα q siRNA ( Figure 7B ; Table 5 ), as expected. In contrast, selective knockdown of Gα q had minimal effect on the capacity of brucine to potentiate the CCh-stimulated ERK1/2 phosphorylation ( Figures 7D, 7E ), whereas knockdown of Gα 12 virtually abolished the allosteric potentiation ( Figure 7F ; Table 5 ), consistent with a selective role of Gα 12 activation in mediating the allosteric modulation of the ERK1/2 response.
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
To our knowledge, this study is the first to use the yeast system to detect functional selectivity of an allosteric ligand, and to show that brucine is capable of exhibiting pathway selectivity. Furthermore, using the yeast system and the unique properties of brucine at the K 7.32 E mutant as pharmacological tools allowed us to determine a putative G protein candidate for brucine biased modulation of M 3 K 7.32 E mAChR-mediated ERK1/2 phosphorylation pathway in mammalian (CHO) cells.
There have been numerous studies investigating the properties of allosteric ligands that bind at mAChRs (Gregory et al., 2007) , with the majority focusing on ligands that bind to the 'prototypical' binding site. Indeed, mutagenesis studies have mapped extracellular regions of mAChRs to determine amino acids residues that are pivotal for allosteric binding of the prototypical modulator, gallamine, and associated ligands (Buller et al., 2002; Gnagey et al., 1999) . However, most of these studies focused on the effects of mutagenesis on radioligand binding, or only used a single signaling endpoint to define functional pharmacology (e.g. Jakubik et al. (1996) ; Iarriccio (2008)). In contrast, our current study investigated the ability of brucine to engender functional selectivity at the M 3 K 7.32 E mAChR by adopting the use of the yeast signaling assay as a predictive screen in conjunction with a multi-platform approach for mammalian system validation. The results produced in all of the yeast strains expressing the rM 3 Δ i3 mAChR showed that brucine had no effect on CCh signaling, which was confirmed in CHO M 3 mAChR cells. This result is consistent with what was found by Iarriccio (2008) . The data generated from the yeast signaling assays at the K 7.32 E mutant, however, suggested that brucine was an agonist with modest enhancement of CCh signaling when coupled to G q -mediated pathways. These data are concordant with those generated for mAChR is also consistent with evidence from previous studies at the same receptor (Lazareno et al., 1998) . However, despite the cooperativities being similar, there was a discrepancy between the affinity estimates of brucine at the unoccupied M 3 mAChR from binding studies (Table 3) Given that the purpose of the current study was predominantly to provide proof of concept in the utility of pairing a yeast screening assay with a functionally selective allosteric ligand, we also attempted to ascertain whether this pairing can provide insights into a convergent This article has not been copyedited and formatted. The final version may differ from this version. involves additional, e.g. G protein-independent components, and/or that the degree of knockdown was insufficient to overcome the high efficacy of the agonist for receptor activation. However, the abolishment of brucine's allosteric effect on the CCh response in ERK1/2 phosphorylation assays by Gα 12 siRNA clearly indicated that the allosteric modulator can promote a unique conformation that recruits Gα 12 to converge on receptor coupling to the ERK1/2-response, further validating the use of the yeast assay as a predictor of this novel property.
Results from this study also suggest that residue 7.32 is not necessarily vital for either orthosteric ligand or brucine binding; instead it may be an important region for maintaining the flexibility, and hence possibly activation, of the receptor. Although the finer points of GPCR activation are still largely unknown, there is evidence that some residues in TMVII can form intramolecular interactions with residues in TMIII, to increase the stability of the receptor in an inactive state in the angiotensin II type 1 receptor and opsin, suggesting that studies that amino acid residues in TMI interact with residues at the bottom of TMVII, and that a large conformational change occurs at the bottom of TMVII upon application of agonist (Wess et al., 2008) . There is also evidence that basic amino acid residues (such as lysine) in membrane proteins 'snorkel' in the lipid, and potentially interact with the charged head-groups in the phospholipid membrane (Mishra et al., 1994) . Furthermore, a lysine residue at the juxtamembrane region of a TM helix has been shown to be important for coordinating the helix with the membrane and is also a determinant for the helical tilt (de Planque et al., 1999; Ozdirekcan et al., 2005) . Therefore, perhaps, the K 7.32 E mutation in the M 3 mAChR alters the interaction of TMVII with the plasma membrane and, in turn, increases the propensity of the receptor to be activated/modulated by brucine. Irrespective of the mode of receptor activation induced by ligands acting at the K 7.32 E mutation, it is clear that the cooperativity between brucine and CCh is increased by the presence this mutation.
In conclusion, this study has provided evidence that the yeast signaling assay is a tractable and valuable platform for the determination of GPCR ligand-G protein functional selectivity profiles mediated by an allosteric ligand, as well as the provision of pharmacological parameters such as affinity, cooperativity and relative efficacy estimates. It is envisaged that this approach should be applicable to any GPCR than can be successfully expressed in yeast.
MOL #64253 MOL #64253
Gnagey Tables   Table 1 Operational 
